Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. 2005

Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
Department of Cell and Cancer Biology, NCI, National Institutes of Health, Rockville, Maryland 20850, USA.

Overexpression of c-Jun enables Rat1a cells to grow in an anchorage-independent manner. We used an inducible c-Jun system under the regulation of doxycycline in Rat1a cells to identify potential c-Jun target genes necessary for c-Jun-induced anchorage-independent growth. Induction of c-Jun results in sustained expression of cyclin A in the nonadherent state with only minimal expression in the absence of c-Jun. The promoter activity of cyclin A2 was 4-fold higher in Rat1a cells in which c-Jun expression was induced compared with the control cells. Chromatin immunoprecipitation demonstrated that c-Jun bound directly to the cyclin A2 promoter. Mutation analysis of the cyclin A2 promoter mapped the c-Jun regulatory site to an ATF site at position -80. c-Jun was able to bind to this site both in vitro and in vivo, and mutation of this site completely abolished promoter activity. Cyclin A1 was also elevated in c-Jun-overexpressing Rat1a cells; however, c-Jun did not regulate this gene directly, since it did not bind directly to the cyclin A1 promoter. Suppression of cyclin A expression via the introduction of a cyclin A antisense sequences significantly reduced the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. Taken together, these results suggest that cyclin A is a target of c-Jun and is necessary but not sufficient for c-Jun-induced anchorage-independent growth. In addition, we demonstrated that the cytoplasmic oncogenes Ras and Src transcriptionally activated the cyclin A2 promoter via the ATF site at position -80. Using a dominant negative c-Jun mutant, TAM67, we showed that this transcriptional activation of cyclin A2 requires c-Jun. Thus, our results suggest that c-Jun is a mediator of the aberrant cyclin A2 expression associated with Ras/Src-induced transformation.

UI MeSH Term Description Entries
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D008957 Models, Genetic Theoretical representations that simulate the behavior or activity of genetic processes or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Genetic Models,Genetic Model,Model, Genetic
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA

Related Publications

Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
April 2005, Molecular and cellular biology,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
October 1992, Oncogene,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
June 1997, Molecular and cellular biology,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
December 1998, The Journal of biological chemistry,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
February 2011, PloS one,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
January 2014, BioMed research international,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
June 2014, Molecular carcinogenesis,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
May 2003, Oncogene,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
January 2006, Oncogene,
Motoo Katabami, and Howard Donninger, and Fumihiro Hommura, and Virna D Leaner, and Ichiro Kinoshita, and Jeffrey F B Chick, and Michael J Birrer
March 2014, Molecular oncology,
Copied contents to your clipboard!